These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 10847473)

  • 1. Long-term octreotide treatment of metastatic carcinoid tumor.
    Corleto VD; Angeletti S; Schillaci O; Marignani M; Caratozzolo M; Panzuto F; Annibale B; Delle Fave G
    Ann Oncol; 2000 Apr; 11(4):491-3. PubMed ID: 10847473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of somatostatin receptor subtype 2 in carcinoid tumors by immunohistochemical investigation with somatostatin receptor subtype 2 antibodies.
    Janson ET; Stridsberg M; Gobl A; Westlin JE; Oberg K
    Cancer Res; 1998 Jun; 58(11):2375-8. PubMed ID: 9622077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours.
    Nilsson O; Kölby L; Wängberg B; Wigander A; Billig H; William-Olsson L; Fjälling M; Forssell-Aronsson E; Ahlman H
    Br J Cancer; 1998 Feb; 77(4):632-7. PubMed ID: 9484822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Different response to the long-acting somatostatin analogues lanreotide and octreotide in a patient with a malignant carcinoid.
    Raderer M; Kurtaran A; Scheithauer W; Fiebiger W; Weinlaender G; Oberhuber G
    Oncology; 2001; 60(2):141-5. PubMed ID: 11244329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study.
    Pivonello C; Rousaki P; Negri M; Sarnataro M; Napolitano M; Marino FZ; Patalano R; De Martino MC; Sciammarella C; Faggiano A; Rocco G; Franco R; Kaltsas GA; Colao A; Pivonello R
    Endocrine; 2017 Jun; 56(3):603-620. PubMed ID: 27688013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single dose of octreotide stabilize metastatic gastro-entero-pancreatic endocrine tumours.
    Angeletti S; Corleto VD; Schillaci O; Moretti A; Panzuto F; Annibale B; Delle Fave G
    Ital J Gastroenterol Hepatol; 1999; 31(1):23-7. PubMed ID: 10091100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term survival of atypical bronchial carcinoids with liver metastases, treated with octreotide.
    Filosso PL; Ruffini E; Oliaro A; Papalia E; Donati G; Rena O
    Eur J Cardiothorac Surg; 2002 May; 21(5):913-7. PubMed ID: 12062286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous octreotide treatment of a growth hormone-releasing hormone-secreting bronchial carcinoid: superiority of continuous versus intermittent administration to control hormonal secretion.
    Lefebvre S; De Paepe L; Abs R; Rahier J; Selvais P; Maiter D
    Eur J Endocrinol; 1995 Sep; 133(3):320-4. PubMed ID: 7581949
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung.
    Papotti M; Croce S; Macrì L; Funaro A; Pecchioni C; Schindler M; Bussolati G
    Diagn Mol Pathol; 2000 Mar; 9(1):47-57. PubMed ID: 10718213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The presence of somatostatin receptors in malignant neuroendocrine tumor tissue predicts responsiveness to octreotide.
    Kvols LK; Reubi JC; Horisberger U; Moertel CG; Rubin J; Charboneau JW
    Yale J Biol Med; 1992; 65(5):505-18; discussion 531-6. PubMed ID: 1364090
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Carcinoid tumor and intravenous octreotide infusion during labor and delivery.
    Le BT; Bharadwaj S; Malinow AM
    Int J Obstet Anesth; 2009 Apr; 18(2):182-5. PubMed ID: 19200714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of type I gastric neuroendocrine tumors with somatostatin analogs.
    Khuroo MS; Khuroo MS; Khuroo NS
    J Gastroenterol Hepatol; 2010 Mar; 25(3):548-54. PubMed ID: 20074162
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of the somatostatin analogue octreotide acetate in the treatment of encephalopathy associated with carcinoid tumor. Case report.
    Siu LL; Chapman W; Moore MJ
    Am J Clin Oncol; 1997 Dec; 20(6):558-61. PubMed ID: 9391539
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Octreotide therapy in carcinoid disease.
    Bax ND; Woods HF; Batchelor A; Jennings M
    Anticancer Drugs; 1996 Jan; 7 Suppl 1():17-22. PubMed ID: 8822081
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carcinoid tumor regression with high-dose octreotide acetate: a patient report.
    Lokich J
    Am J Clin Oncol; 1998 Jun; 21(3):246-7. PubMed ID: 9626790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Octreotide LAR in carcinoid: how to dose?
    Yao JC; Kvols LK
    Pancreas; 2008 Oct; 37(3):337-8; author reply 338-9. PubMed ID: 18815562
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan).
    Hillman N; Herranz L; Alvarez C; Martínez Olmos MA; Márco A; Gómez-Pan A
    Exp Clin Endocrinol Diabetes; 1998; 106(3):226-30. PubMed ID: 9710364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 111In-octreotide scintigraphy in endocrine tumors. Preliminary data.
    Cremonini N; Furno A; Sforza A; Chiarini V; Graziano E; Zampa G; Turba E
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):116-20. PubMed ID: 9002767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ectopic growth hormone-releasing hormone secretion by a metastatic bronchial carcinoid tumor: a case with a non hypophysial intracranial tumor that shrank during long acting octreotide treatment.
    Fainstein Day P; Frohman L; Garcia Rivello H; Reubi JC; Sevlever G; Glerean M; Fernandez Gianotti T; Pietrani M; Rabadan A; Racioppi S; Bidlingmaier M
    Pituitary; 2007; 10(3):311-9. PubMed ID: 17373589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intractable hypercalcemia due to a metastatic carcinoid secreting parathyroid hormone-related peptide and interleukin-6: response to octreotide.
    Barhoum M; Hutchins L; Fonseca VA
    Am J Med Sci; 1999 Sep; 318(3):203-5. PubMed ID: 10487414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.